The first malaria vaccine has been approved for use in Ghana. Malaria is a disease that kills 620,000 people annually, most of whom are children.
The R21 Vaccine, developed by scientists at the University of Oxford, is expected to revolutionise the centuries-long fight against malaria.
For over a century, scientists have been attempting to develop a vaccine.
The vaccine is already being considered for global approval by the World Health Organization.
The R21 Vaccine has been shown in trials to be 80% effective in protecting against malaria, in trials. It is given in three doses, with a later one-year booster.
The Serum Institute of India plans to begin production of 100-200 million doses per year and will most likely establish a factory in Ghana.
Malaria is primarily transmitted by a specific type of mosquito and primarily affects tropical countries in Africa, Asia, South America, and Central America.